ADAPTIVE BIOTECHNOLOGIES CORPORATION Proceeds from Contributed Capital
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Proceeds from Contributed Capital of $2.48 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromContributedCapital · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for the quarter ending 2026-06-30 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for the quarter ending 2026-03-31 was $2.48M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for the quarter ending 2025-06-30 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for the quarter ending 2025-03-31 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for fiscal 2025 was $12.52M.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for fiscal 2024 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for fiscal 2023 was $0.00.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION proceeds from contributed capital for fiscal 2021 was $429.00K.
| Period end | Proceeds from Contributed Capital 3 month | Proceeds from Contributed Capital 6 month | Proceeds from Contributed Capital 9 month | Proceeds from Contributed Capital 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $2.48M 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | $2.48M 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | $12.52M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 derived: sum of 3 quarters · filed 2024-02-29 | $429.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $429.00K 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $429.00K 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $429.00K 10-Q · filed 2022-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |